AC Immune (ACIU) Other Non-Current Assets (2014 - 2025)
AC Immune (ACIU) reported Other Non-Current Assets of $730683.2 for Q4 2025, up 54.24% year-over-year from $473731.6 in Q4 2024, and little changed on a QoQ basis from $730064.0 in Q3 2025.
AC Immune (ACIU) has 12 years of Other Non-Current Assets data on file, last reported at $730683.2 in Q4 2025.
- Quarterly Other Non-Current Assets rose 54.24% year-over-year to $730683.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $730683.2 (up 54.24% YoY) and the FY2025 annual result came in at $704379.0, up 48.69% from the prior year.
- Other Non-Current Assets held at $730683.2 in Q4 2025 per ACIU's latest filing, from $730064.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $407.0 million in Q4 2023 and bottomed at $373799.8 in Q3 2022.
- The 5-year median for Other Non-Current Assets is $477227.1 (2024), against an average of $98.5 million.
- The widest annual swing landed in 2021, when Other Non-Current Assets surged 126077.32%; it then plunged 99.91% in 2022.
- Tracing ACIU's Other Non-Current Assets over 5 years: stood at $393.7 million in 2021, then sank by 99.9% to $374725.9 in 2022, then surged by 108506.04% to $407.0 million in 2023, then sank by 99.88% to $473731.6 in 2024, then soared by 54.24% to $730683.2 in 2025.
- Per Business Quant, the three latest ACIU Other Non-Current Assets figures stand at $730683.2 (Q4 2025), $730064.0 (Q3 2025), and $705407.9 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 730,683.16 |
| Sep 30, 2025 | 730,063.96 |
| Jun 30, 2025 | 705,407.89 |
| Mar 31, 2025 | 650,666.56 |
| Dec 31, 2024 | 473,731.57 |
| Sep 30, 2024 | 478,996.01 |
| Jun 30, 2024 | 458,904.30 |
| Mar 31, 2024 | 475,458.16 |
| Dec 31, 2023 | 406.97 Mn |
| Sep 30, 2023 | 408,707.08 |
| Jun 30, 2023 | 401,495.37 |
| Mar 31, 2023 | 390,299.69 |
| Dec 31, 2022 | 374,725.91 |
| Sep 30, 2022 | 373,799.85 |
| Jun 30, 2022 | 374,823.78 |
| Mar 31, 2022 | 393,059.44 |
| Dec 31, 2021 | 393.67 Mn |
| Sep 30, 2021 | 395.35 Mn |
| Jun 30, 2021 | 398.08 Mn |
| Mar 31, 2021 | 369.42 Mn |
| Dec 31, 2020 | 369,455.98 |
| Sep 30, 2020 | 330,255.11 |
| Jun 30, 2020 | 315,494.81 |
| Mar 31, 2020 | 314,289.36 |
| Dec 31, 2019 | 307,156.62 |
| Sep 30, 2019 | 308,545.21 |
| Jun 30, 2019 | 303.18 |
| Mar 31, 2019 | 305,235.01 |
| Dec 31, 2018 | 305,469.78 |
| Sep 30, 2018 | -85,376.69 |
| Jun 30, 2018 | -85,340.22 |
| Mar 31, 2018 | -88,570.12 |
| Dec 31, 2017 | 127,710.99 |
| Sep 30, 2017 | -41.57 Mn |
| Jun 30, 2017 | -40,599.95 |
| Mar 31, 2017 | -39,838.54 |
| Dec 31, 2016 | 86,002.10 |
| Dec 31, 2015 | 85,895.22 |
| Dec 31, 2014 | 164,977.84 |